NDAINTRAVENOUSPOWDER
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
MICAFUNGIN (micafungin) by Pfizer is [see microbiology ()] . First approved in 2021.
Drug data last refreshed 5h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Micafungin is an intravenous antifungal powder approved by the FDA in June 2021 under Pfizer sponsorship. It is an echinocandin-class antifungal that inhibits fungal cell wall synthesis. The drug is indicated for treatment of invasive fungal infections in hospitalized patients.
Peak
Product is in peak commercial stage with moderate competitive pressure (30%), suggesting stable market presence and established sales infrastructure.
Mechanism of Action
[see Microbiology ()] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Micafungin Pharmacokinetics in Obese Patients
Started Jan 2017
24 enrolled
Morbid Obesity
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
Started Sep 2015
66 enrolled
Acute Leukemia
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
Started May 2015
35 enrolled
Candidiasis, SystemicCandida Meningitis
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
Started Mar 2015
2,555 enrolled
Invasive Fungal Infections
Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology
Started Jul 2014
150 enrolled
Antifungal ProphylaxisHaemopathy
Worked on MICAFUNGIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.